This post was originally published on this site Funded by a $380,000 grant from the National Cancer Institute, researchers at the University at Buffalo (UB) in New York and Moscow State University in Russia are collaborating to study a potential biomarker for metastatic prostate cancer, and determine how to best detect it. While some prostate…
This post was originally published on this site PGT, an experimental chemotherapy developed by OncBioMune, inhibited the growth of ovarian cancer cells resistant to multiple chemotherapeutic agents. These preliminary results suggest that the therapy could potentially be used to treat tumors that do not respond to standard chemotherapy. PGT is a combination of paclitaxel, gallium,…
This post was originally published on this site The candidate CAR-T cell therapy bb2121 showed a favorable safety profile and eliminated traces of cancer in nearly half of heavily pre-treated multiple myeloma patients included in a Phase 1 clinical trial, interim results show. The study, “Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple…
This post was originally published on this site The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) submitted by Prestige BioPharma for HD201, its lead biosimilar to Genentech‘s Herceptin (trastuzumab). Like Herceptin, HD201 is indicated for the treatment of women with HER2-positive breast cancer. Prestige’s lead biosimilar candidate also is indicated…
This post was originally published on this site The sandwich generation is one of the many terms that define caregiving. As you can guess, the term has nothing to do with two pieces of bread spread with peanut butter and jelly. Rather, the sandwich generation refers to those who currently are raising children or supporting…
This post was originally published on this site ProMIS Neurosciences researchers have discovered new antibody candidates that selectively bind to the neurotoxic form of the tau protein — one of the hallmarks of Alzheimer’s disease. These new antibodies join the company’s PMN310, a humanized antibody that attacks only toxic forms of the amyloid beta protein…
This post was originally published on this site DPX-Survivac combined with intermittent low-dose cyclophosphamide can generate significant anti-tumor immune responses that correlate with tumor regression in women with recurrent advanced ovarian cancer, latest results from the DECIDE1 Phase 2 trial show. Interim data announced by DPX-Survivac‘s developer, IMV, revealed that all 15 patients with smaller tumors…
This post was originally published on this site Treatment with Pomalyst (pomalidomide) in combination with Velcade (bortezomib) and dexamethasone prolongs survival without disease worsening in patients with multiple myeloma who have failed prior treatments, including Revlimid (lenalidomide), results from a pivotal clinical trial show. Building on this data, the European Commission recently approved the triple combo as an early…
This post was originally published on this site Men who are diagnosed with prostate cancer at later stages of the disease are more likely to say that their disease has affected several aspects of their life, including their self-esteem, how they share feelings with others, and how they feel about their sexual health, a survey…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has accepted Cue Biopharma‘s investigational new drug (IND) application for its immunotherapy candidate CUE-101, clearing the way for the first-in-human Phase 1 trial in people with head and neck squamous cell carcinoma (HNSCC) caused by human papillomavirus (HPV). CUE-101 is…
